With vaccine development prioritized during the COVID-19 pandemic, innovations have to accelerated development processes.

Overcoming Vaccine Development Challenges

The inhaled route of administration for biologics is experiencing renewed interest.

Taking a Breath: Advances in Inhaled Biologics

Topic

Articles

Researchers from the Chalmers University of Technology and AstraZeneca have developed a new method of detecting and testing lipid nanoparticles.

Novel Automated Process May Speed Up Development of New Medicines

VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.

VIVEbiotech Launches Lentiviral Vector Manufacturing Plant for Cell and Gene Therapies

FDA has granted fast track designation to a GLP-1/glucagon dual agonist in development by Boehringer Ingelheim and Zealand Pharma for the treatment of NASH.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for NASH Treatment

FDA has granted Janssen breakthrough therapy designation for teclistamab, an investigational bispecific antibody under development for treating relapsed or refractory multiple myeloma.

Janssen Receives FDA Breakthrough Therapy Designation for Multiple Myeloma mAb

Well-defined studies are crucial to effective process development.

Common Challenges in Cross-Functional Process Development

Through the acquisition, Aceto can now offer its customers support throughout the drug development process and access to North American manufacturing for APIs and advanced intermediates.

Aceto to Acquire Cascade Chemistry

GoSilico’s software for digital twins of downstream biopharmaceutical processes will be integrated into Cytiva.

Cytiva Acquires German Software Maker GoSilico 

Currently, PNI offers a Genetic Medicine Toolkit, including its GenVoy LNP delivery platform and NanoAssemblr microfluidic-based nanoparticle manufacturing platform, for the development of genetic medicines.

PNI to be Acquired by Danaher Corporation’s Life Sciences Platform

Feliza Mirasol is the science editor for 

The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.

Next-Gen Therapies Drive Development Technologies

Yan He is the senior scientist at BioSpherix, Ltd., 25 union St. Parish, NY

Shannon Darou is a technician at BioSpherix, Ltd., 25 union St. Parish, NY

Stassa P.D. Henn is an intern at BioSpherix, Ltd., 25 union St. Parish, NY

Rose Walter is an intern at BioSpherix, Ltd., 25 union St. Parish, NY

Randy Yerden is the chief executive officer at BioSpherix, Ltd., 25 union St. Parish, NY

Alicia D. Henn is the chief scientific officer, all at BioSpherix, Ltd., 25 union St. Parish, NY

Controlling certain atmospheric conditions in a closed NGI processing chamber can reduce bioburden without disinfectants. 